Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival

Leuk Lymphoma. 2009 Oct;50(10):1559-61. doi: 10.1080/10428190903159384.
No abstract available

Publication types

  • Comment
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biopsy
  • Bone Marrow / pathology
  • Chromosome Deletion
  • Chromosomes, Human, Pair 17 / genetics
  • Cyclophosphamide / administration & dosage
  • DNA Mutational Analysis / methods*
  • Frameshift Mutation
  • Gene Expression Regulation, Leukemic*
  • Genes, p53*
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Mutation, Missense
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / genetics*
  • Prognosis
  • Rituximab
  • Survival Analysis
  • Tumor Suppressor Protein p53 / biosynthesis*
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Neoplasm Proteins
  • Tumor Suppressor Protein p53
  • Rituximab
  • Cyclophosphamide
  • Vidarabine
  • fludarabine